Loomis Sayles & Co. L P Raises Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Loomis Sayles & Co. L P raised its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 7.2% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 205,798 shares of the company’s stock after acquiring an additional 13,880 shares during the quarter. Loomis Sayles & Co. L P’s holdings in Medpace were worth $68,696,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Ashton Thomas Securities LLC purchased a new position in Medpace in the 3rd quarter valued at about $37,000. DT Investment Partners LLC acquired a new position in shares of Medpace during the second quarter valued at approximately $41,000. Capital Performance Advisors LLP purchased a new position in shares of Medpace in the third quarter valued at approximately $46,000. Ashton Thomas Private Wealth LLC purchased a new position in shares of Medpace in the second quarter valued at approximately $52,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of Medpace in the first quarter worth approximately $54,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of Medpace stock opened at $337.75 on Monday. The stock has a 50 day moving average of $340.14 and a 200 day moving average of $373.03. The firm has a market capitalization of $10.50 billion, a price-to-earnings ratio of 29.58, a PEG ratio of 1.87 and a beta of 1.37. Medpace Holdings, Inc. has a fifty-two week low of $268.80 and a fifty-two week high of $459.77.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, October 21st. The company reported $3.01 EPS for the quarter, beating the consensus estimate of $2.77 by $0.24. The business had revenue of $533.32 million for the quarter, compared to analyst estimates of $540.99 million. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The company’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.22 EPS. Analysts forecast that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently commented on MEDP shares. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and reduced their price objective for the company from $415.00 to $345.00 in a research note on Wednesday, September 25th. UBS Group cut shares of Medpace from a “buy” rating to a “neutral” rating and reduced their target price for the company from $420.00 to $350.00 in a research report on Friday, September 27th. StockNews.com downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. William Blair reaffirmed an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Finally, Robert W. Baird boosted their price objective on Medpace from $349.00 to $354.00 and gave the stock a “neutral” rating in a research note on Monday. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, Medpace has a consensus rating of “Hold” and an average target price of $380.56.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.